Please try another search
For the nine months ended 30 September 2019, Sophiris Bio Inc revenues was not reported. Net loss decreased 55% to $5.5M. Lower net loss reflects Gain on revaluation of warrant liability increase from $143K to $2.1M (income), Interest Expense decrease of 8% to $471K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.41 to -$0.18.
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -2.13 | -2.31 | -2.81 | -2.93 |
Net Income | -0.96 | -2.16 | -2.36 | 5.52 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 7.1 | 6.44 | 9.61 | 13.2 |
Total Liabilities | 9.86 | 8.82 | 10.01 | 11.46 |
Total Equity | -2.76 | -2.38 | -0.4 | 1.74 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 0 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -8.43 | -5.74 | -3.42 | -13.46 |
Cash From Investing Activities | -0.48 | 0.51 | 0.21 | 8.27 |
Cash From Financing Activities | 2.16 | -0.8 | -0.1 | 0.1 |
Net Change in Cash | -6.75 | -6.03 | -3.32 | -5.09 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review